1
|
Yagi S, Furukawa S, Tange K, Ninomiya T, Suzuki S, Ohashi K, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. ABO Blood Type and Clinical Characteristics Among Japanese Patients With Ulcerative Colitis. Cureus 2024; 16:e59787. [PMID: 38846206 PMCID: PMC11154843 DOI: 10.7759/cureus.59787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/06/2024] [Indexed: 06/09/2024] Open
Abstract
Background The ABO blood type has been associated with several digestive diseases. Some evidence has shown an association between ABO blood type and clinical outcomes among Asian patients with Crohn's disease. However, there are no reports about the association between ABO blood type and clinical outcomes in ulcerative colitis (UC). In this study, we aimed to evaluate the association between ABO blood type and clinical characteristics among patients with UC. Methodology The study subjects consisted of 277 Japanese patients with UC. Information on clinical characteristics and ABO blood type data was collected using medical records and a self-reported questionnaire. The information on clinical remission was collected using medical records. The definition of mucosal healing (MH) and partial MH was Mayo endoscopic subscore of 0 or 0-1, respectively. Results Of the enrolled patients, 39.4% (109/277), 18.4% (51/277), 29.2% (81/277), and 13.0% (36/277) had blood types A, B, O, and AB, respectively. The mean current age, age at onset of UC, and body mass index were 51.3 years, 42.1 years, and 22.7 kg/m2, and the proportion of male patients was 59.2% (164/277). The proportion of patients with clinical remission, MH, partial MH, and prednisolone use were 58.1% (161/277), 25.6% (71/277), 63.2% (175/277), and 21.3% (59/277), respectively. Conclusions None of the blood types were associated with any of the variables in this study. Among Japanese patients with UC, ABO blood type might not be associated with clinical characteristics.
Collapse
Affiliation(s)
- Sen Yagi
- Department of Internal Medicine, Saiseikai Imabari Hospital, Imabari, JPN
| | | | - Kazuhiro Tange
- Department of Inflammatory Bowel Diseases and Therapeutics, Ehime University, Toon, JPN
| | - Tomoyuki Ninomiya
- Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, JPN
| | - Seiyuu Suzuki
- Department of Gastroenterology, Sumitomo Besshi Hospital, Niihama, JPN
| | | | | | - Eiji Takeshita
- Department of Inflammatory Bowel Diseases and Therapeutics, Ehime University, Toon, JPN
| | - Yoshio Ikeda
- Endoscopy Center, Ehime University Hospital, Toon, JPN
| | - Yoichi Hiasa
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, JPN
| |
Collapse
|
2
|
Yang H, Yan J. A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. Medicine (Baltimore) 2022; 101:e30893. [PMID: 36181128 PMCID: PMC9524977 DOI: 10.1097/md.0000000000030893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Bladder cancer (BC) is the 10th most common malignancy worldwide, and some studies reported that ABO blood type or/and rhesus factor has been identified as a prognostic oncologic marker for patients with BC. We carried out a systematic review to assess the prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. METHODS We searched databases through February 2022 for studies assessing blood group on outcomes in patients with bladder cancer. RESULTS We included ten studies with 15,204 participants. We found that blood type A is relevant to non-muscle-invasive BC patients treated with transurethral resection of bladder tumor and blood type B patients have a lower incidence of disease recurrence and progression. Blood type O and non-O blood type have not been found to be related to disease recurrence. However, in multivariable analyses, blood type O and non-O blood type are associated with cancer-specific mortality (CSM). Other than that, blood type B doesn't have statistical significance for BC patients accepted radical cystectomy (RC). The same results showed in blood type AB non-muscle-invasive bladder cancer patients treated with RC. CONCLUSIONS Our study confirmed that a particular association of blood type for prognosis of patients with BC, and ABO blood group antigen expression can be suitable biomarkers for BC. We also found that rhesus factor has no impact on prognosis of BC patients.
Collapse
Affiliation(s)
- Haiming Yang
- Department of Interventional Therapy, Qinghai University, Xining, China
| | - Jingxin Yan
- Department of Interventional Therapy, Qinghai University, Xining, China
- Department of Postgraduate, Qinghai University, Xining, China
- *Correspondence: Jingxin Yan, Department of Interventional Therapy, Affiliated Hospital of Qinghai University, Xining 810001, China (e-mail: )
| |
Collapse
|
3
|
Zelga P, Hernández-Barco YG, Qadan M, Ferrone CR, Baba T, Bolm L, Jah A, Warshaw AL, Lillemoe KD, Balakrishnan A, Fernández-Del Castillo C. ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN). Pancreatology 2022; 22:264-269. [PMID: 35000863 DOI: 10.1016/j.pan.2021.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 12/21/2021] [Accepted: 12/22/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND The ABO blood type has been associated with risk of development of several malignancies, including pancreatic cancer. Data regarding IPMN is equivocal. To investigate this further, we analyzed the association between the ABO blood group and the presence of malignancy in a large cohort of resected IPMN and its influence in survival. METHODS 819 patients who underwent pancreatic resection for IPMN in the Massachusetts General Hospital (MGH) and Cambridge University Hospitals NHS Foundation Trust (CUH) from January 1993 to December 2020 were identified from prospective institutional databases. Pathological characteristics and blood type were correlated. RESULTS The distribution of blood types A, B, AB and O was 384 (47%), 92 (11%), 44 (5%) and 299 (37%), respectively. This blood type distribution was different than the reference population of the MGH and the CUH, which is 55% non-O blood group, and 45% type O. There was a significant predominance of non-O blood types when compared with O-blood type in patients with malignant IPMN (i.e. patients with high-grade dysplasia and invasive cancer) (67% vs 33%, OR 1.31 95%CI: 0.98-1.75, p = 0.069). The association was stronger for IPMN with invasive cancer (OR 1.43 95%CI: 1.01-2.02, p = 0.039). Blood group did not influence survival. CONCLUSION Non-O blood type is associated with need for resection in IPMN and with presence of invasive carcinoma.
Collapse
Affiliation(s)
- Piotr Zelga
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Surgery, Addenbrookes Hospital, NIHR Comprehensive Biomedical Research and Academic Health Sciences Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom
| | - Yasmin G Hernández-Barco
- Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Motaz Qadan
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Cristina R Ferrone
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Taisuke Baba
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Louisa Bolm
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Asif Jah
- Department of Surgery, Addenbrookes Hospital, NIHR Comprehensive Biomedical Research and Academic Health Sciences Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom
| | - Andrew L Warshaw
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Keith D Lillemoe
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Anita Balakrishnan
- Department of Surgery, Addenbrookes Hospital, NIHR Comprehensive Biomedical Research and Academic Health Sciences Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom
| | | |
Collapse
|
4
|
Ergun Y, Esen SA, Bardakci M, Ucar G, Kalkan Z, Urakci Z, Seyran E, Dogan M, Eren T, Aslan V, Kahraman S, Genc EE, Acikgoz Y, Dirikoc M, Esen I, Uncu D. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors. Cancer Biomark 2022; 34:329-336. [PMID: 35001878 DOI: 10.3233/cbm-210455] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now. OBJECTIVE In this study, the relationship between different blood groups and nivolumab treatment response in patients with advanced malignant melanoma was investigated. METHODS The data of patients who used nivolumab for advanced malignant melanoma between April 2018 and April 2021 were retrospectively reviewed. RESULTS A total of 73 patients were included in the study. In the progression-free survival (PFS) analysis according to blood groups, it was 3.9 months, 16.1 months, 20.0 months and 3.0 months for A, B, AB and O, respectively (p= 0.1). Overall survival (OS) analysis according to blood groups was 5.1 months, 25.0 months, 20.0 months and 9.3 months for A, B, AB and O, respectively (p= 0.1). The B antigen group (B or AB) had significantly longer PFS and OS than the non-B antigen group (A or O) (16.1 vs. 3.5 months for PFS, respectively, p= 0.03; 20.0 vs. 7.4 months for OS, respectively, p= 0.02). CONCLUSIONS The presence of B antigen provides a significant advantage in terms of survival in patients using ICIs for advanced melanoma.
Collapse
Affiliation(s)
- Yakup Ergun
- Department of Medical Oncology, Batman Training and Research Hospital, Batman, Turkey
| | - Selin Akturk Esen
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Murat Bardakci
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Gokhan Ucar
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Ziya Kalkan
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
| | - Zuhat Urakci
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
| | - Erdogan Seyran
- Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Mutlu Dogan
- Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Tulay Eren
- Department of Medical Oncology, UHS Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
| | - Volkan Aslan
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Seda Kahraman
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Emine Eylem Genc
- Department of Hematology, Batman Training and Research Hospital, Batman, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Merve Dirikoc
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Irfan Esen
- Department of Internal Medicine, VM Medical Park (Kecioren) Hospital, Ankara, Turkey
| | - Dogan Uncu
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| |
Collapse
|
5
|
Jing SW, Xu Q, Zhang XY, Jing ZH, Zhao ZJ, Zhang RH, Wu FP, Wang J. Are People With Blood Group O More Susceptible to Nasopharyngeal Carcinoma and Have Worse Survival Rates? A Systematic Review and Meta-Analysis. Front Oncol 2021; 11:698113. [PMID: 34490093 PMCID: PMC8417737 DOI: 10.3389/fonc.2021.698113] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 08/02/2021] [Indexed: 01/02/2023] Open
Abstract
Objective Nasopharyngeal carcinoma (NPC) is a common malignant tumour in Southeast Asia, especially in southern China. ABO blood groups have been proven to play an important role in many cancers. However, it is still controversial whether the ABO blood group has a definite relationship to susceptibility to NPC and the prognosis of NPC patients. This meta-analysis was performed to elucidate the correlation between ABO blood group and NPC to provide more data for clinical practice. Methods A systematic search was performed of the Chinese National Knowledge Infrastructure (CNKI), Wanfang, Web of Science, EMBASE, and PubMed databases up to December 31, 2020. Stata 11.0 statistical software was used for this meta-analysis. Results According to the inclusion and exclusion criteria, a total of 6 studies including 6938 patients with NPC were selected. Blood group O was relevant to Chinese NPC patients, and patients with blood group O had a significantly lower incidence of NPC, while blood group A had no correlation with susceptibility to NPC. There was no difference in the 3-year overall survival (OS), locoregional relapse-free survival (LRRFS) or distant metastasis-free survival (DMFS) rates between patients with blood group O and those with non-O blood groups; worse 5-year OS, LRRFS and DMFS rates were found in patients with blood group O, whereas blood group A was not related to prognosis. Conclusion Blood group O in Chinese patients with NPC seems to be a protective factor for morbidity. However, once patients with blood group O are diagnosed with NPC, this blood group often indicates unfavourable OS, LRRFS and DMFS rates. It is recommended that more attention should be paid to the influence of blood group factor on patients in the treatment of NPC.
Collapse
Affiliation(s)
- Shao-Wu Jing
- Department of Radiation Oncology, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Qing Xu
- Department of Ultrasound, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Xin-Yuan Zhang
- Department of Radiation Oncology, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Zhong-Hao Jing
- Department of Radiation Oncology, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Zhi-Jun Zhao
- Otorhinolaryngology Head and Neck Surgery, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Ruo-Hui Zhang
- Department of Radiation Oncology, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Feng-Peng Wu
- Department of Radiation Oncology, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Jun Wang
- Department of Radiation Oncology, Fouth Hospital of Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
6
|
Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up. Urol Oncol 2021; 39:736.e9-736.e16. [PMID: 34247906 DOI: 10.1016/j.urolonc.2021.06.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/02/2021] [Accepted: 06/08/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND The ABO blood group system has been previously discussed as a risk factor to develop, as well as a prognostic factor in non-metastatic renal cell carcinoma (RCC). Controversial findings have been reported in different populations of RCC patients with rather short follow-up periods. In this study, we aimed to clarify the distribution and prognostic role of ABO blood groups upon 15 years of median follow-up in non-metastatic RCC patients. MATERIALS AND METHODS We evaluated the distribution and prognostic significance of ABO blood group system in two independent cohorts (n = 405 and n = 1473) of non-metastatic RCC patients, who underwent curative (partial or total) nephrectomy between 1998 and 2012 at two tertiary academic centers. Cancer-specific survival, metastasis-free survival, as well as overall survival (OS) were assessed using the Kaplan-Meier method, univariable- and multivariable Cox regression models were applied, respectively. RESULTS In the two cohorts, blood groups were not associated with any clinical endpoints (for cohort 2: Cancer-specific survival (HR = 1.233; 95%CI 0.998-1.523, P = 0.052), metastasis-free survival (HR = 1.161; 95%CI 0.952-1.416, P = 0.142) and OS (HR = 1.037; 95%CI 0.890-1.208, P = 0.641), respectively). Compared to 250.298 healthy blood-donors of the Styrian state, the distribution of blood groups was (624 (42.4%) versus 106.861 (42.7%) in group A, 191 (13%) vs. 34.164 (13.7%) in group B, 575 (39%) versus 93.579 (37.4%) in group O and 83 (5.6%) vs. 15.694 (6.3%), P = 0.467). CONCLUSION In this large study with the longest period of follow-up reported to date, the ABO blood group system could not be validated as a prognostic factor in predicting important clinical endpoints in non-metastatic RCC patients.
Collapse
|
7
|
De Rycke O, Védie AL, Guarneri G, Nin F, De Flori C, Hentic O, Idri S, Sauvanet A, Rebours V, Cros J, Couvelard A, Ruszniewski P, de Mestier L. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. Pancreatology 2020; 20:1718-1722. [PMID: 33032924 DOI: 10.1016/j.pan.2020.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Revised: 09/11/2020] [Accepted: 09/19/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of patients with blood type O is better for pancreatic adenocarcinoma, although this has not been extensively explored in pancreatic neuroendocrine tumors (PanNET). OBJECTIVE To assess the influence of the ABO and Rhesus blood types on the risk of recurrence in patients who underwent curative intent PanNET surgical resection. METHODS All consecutive patients operated on for well-differentiated panNET in an expert center from 2003 to 2018 were retrospectively included. Blood group, Rhesus system, demographic and clinical data were collected. The primary endpoint was recurrence free survival (RFS). Factors associated with RFS were explored using Cox proportional hazard models. RESULTS Overall, 300 patients (male 43%) were included, median age 54 years old (IQR 45-64). The ABO blood group distribution was similar to that of the French population. There was no association between blood group and tumor features. The median postoperative follow-up was 43.9 months (17.0-77.8). The 5- and 10-year RFS rates were 85 ± 4% and 71 ± 13% in O RhD + patients, versus 72 ± 4% and 63 ± 6% otherwise, respectively (p = 0.035). The O RhD + blood group was associated with a decreased risk of recurrence (HR 0.34, 95% CI [0.15-0.75]), p = 0.007 in multivariable analysis adjusted for age, ki67, functioning syndrome, resection margins, tumor size, lymph node status, oncogenetic syndrome. CONCLUSIONS After curative-intent surgical resection for PanNET, patients with a non-O RhD + blood group may have an increased risk of recurrence and could benefit from closer follow-up.
Collapse
Affiliation(s)
- Ophélie De Rycke
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Anne-Laure Védie
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France
| | - Giovanni Guarneri
- Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France
| | - Frédéric Nin
- Établissement Français du Sang Ile de France, Beaujon University Hospital (APHP), Clichy, France
| | - Céline De Flori
- INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Olivia Hentic
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France
| | - Salim Idri
- Établissement Français du Sang Ile de France, Beaujon University Hospital (APHP), Clichy, France
| | - Alain Sauvanet
- Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France
| | - Vinciane Rebours
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Jérôme Cros
- Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital (APHP), Paris/Clichy, France
| | - Anne Couvelard
- Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital (APHP), Paris/Clichy, France
| | - Philippe Ruszniewski
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Louis de Mestier
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France.
| |
Collapse
|
8
|
Williams H, Jajja MR, Hashmi SS, Maxwell D, Cardona K, Maithel SK, Russell MC, Sarmiento JM, Winer JH, Kooby DA. Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. HPB (Oxford) 2020; 22:1557-1562. [PMID: 32146119 DOI: 10.1016/j.hpb.2020.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Revised: 12/06/2019] [Accepted: 01/05/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Existing research suggests patients with blood group O are less likely to develop pancreatic ductal adenocarcinoma (PDAC) compared to those with non-O blood groups, and that survival from PDAC may be affected by ABO blood type. This study assessed survival outcomes in PDAC patients who underwent pancreatoduodenectomy (PD) in one health system. METHODS From 2010 to 2017, demographic, operative, chemotherapy and survival data for patients undergoing PD at Emory Healthcare were reviewed. Patients with blood type AB were excluded due to small sample size. The relationship between ABO blood group and survival was analyzed using Kaplan-Meier survival curves and multivariate cox proportional regression analysis. RESULTS Of 449 PDAC patients assessed, 204 (45.4%), 60 (13.4%) and 185 (41.2%) were blood groups A, B and O, respectively. Patients were well matched in clinicopathologic characteristics. Median survival did not differ by blood group (p = 0.82), and this relationship remained insignificant on cox regression analysis (p = 0.15). On multivariate analysis, lymph node positivity (p < 0.001) and increasing age (p = 0.001) were associated with reduced survival. CONCLUSION In contrast to recent reports, this larger study found that blood group did not impact overall survival among patients undergoing PD for PDAC.
Collapse
Affiliation(s)
| | - Mohammad R Jajja
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Salila S Hashmi
- Department of Anesthesiology, Emory University, Atlanta, GA, USA
| | - Daniel Maxwell
- Department of Surgery, Emory University, Atlanta, GA, USA
| | - Kenneth Cardona
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Shishir K Maithel
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Maria C Russell
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Juan M Sarmiento
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Joshua H Winer
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - David A Kooby
- Department of Surgery, Emory University, Atlanta, GA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
| |
Collapse
|
9
|
Razzaghi N, Seraj H, Heydari K, Azadeh H, Salehi A, Behnamfar M, Bahadori M, Ebrahimi H, Malekan M, Gholamalipour N. ABO Blood Groups Associations with Ovarian Cancer: A Systematic Review and Meta-analysis. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY 2020. [DOI: 10.1007/s40944-020-00463-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
10
|
Li SS, Zhou CY, Liao R, Xiong L, Weng NN, Zhao YQ, Mason C, Gou HF, Yi C, Zhu Q. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2020; 99:e19413. [PMID: 32243360 PMCID: PMC7220786 DOI: 10.1097/md.0000000000019413] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The aim of this observational study was to test whether ABO blood type was a prognostic factor for pancreatic ductal adenocarcinoma (PDAC) patients and whether other risk factors could influence pancreatic cancer patients' survival. This study included 610 patients who were diagnosed as pancreatic cancer and had undergone radical surgery. Patients' characteristics included age, gender, tumor stage, tumor grade, adenosquamous carcinoma (ASC) status, preoperative serum carbohydrate antigen 19-9 (CA19-9) levels, preoperative serum carcinoembryonic antigen (CEA) levels, ABO blood type, smoking status, and drinking status were analyzed in this study. Cox proportional hazards regression model and Kaplan-Meier method were used to evaluate the role of prognostic factors. For pancreatic cancer patients undergoing radical surgery, the overall survival was worse for ASC patients than PDAC patients (Log-rank = 11.315, P < .001). Compared with ASC patients (Log-rank < 0.001, P = .996), PDAC patients can benefit from chemotherapy (Log-rank = 17.665, P < .001). For PDAC patients, O blood type had better overall survival than non-O blood type (Log-rank = 4.153, P = .042). Moreover, the group with higher serum levels of CA19-9 had poor prognosis compared to another group with low serum CA19-9 (Log-rank = 4.122, P = .042). Higher CEA levels indicated poor prognosis (Log-rank = 13.618, P < .001). In conclusion, ASC status was associated with overall survival of pancreatic cancer patients and cannot benefit from postoperative chemotherapy. Non-O blood type was a prognostic factor for PDAC patients.
Collapse
Affiliation(s)
- Shuang-Shuang Li
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Cong-Ya Zhou
- Department of Radiation Oncology, The First Affiliated Hospital, College of Medical, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
| | - Rong Liao
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Lai Xiong
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Ning-Na Weng
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Ya-Qin Zhao
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Clifford Mason
- Department of Obstetrics and Gynecology, University of Kansas School of Medicine, Kansas City, MO, USA
| | - Hong-Feng Gou
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Cheng Yi
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| | - Qing Zhu
- Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan
| |
Collapse
|
11
|
Lu CH, Shih TS, Shih PC, Pendharkar GP, Liu CE, Chen CK, Hsu L, Chang HY, Yang CL, Liu CH. Finger-powered agglutination lab chip with CMOS image sensing for rapid point-of-care diagnosis applications. LAB ON A CHIP 2020; 20:424-433. [PMID: 31872843 DOI: 10.1039/c9lc00961b] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Agglutination is an antigen-antibody reaction with visible expression of aggregation of the antigens and their corresponding antibodies. Applications extend to the identification of acute bacterial infection, hemagglutination, such as blood grouping, and diagnostic immunology. Our finger-powered agglutination lab chip with external CMOS image sensing was developed to support a platform for inexpensive, rapid point-of-care (POC) testing applications related to agglutination effects. In this paper, blood grouping (ABO and Rh grouping) was utilized to demonstrate the function of our finger-powered agglutination lab chip with CMOS image sensing. Blood antibodies were preloaded into the antibody reaction chamber in the lab chip. The blood sample was pushed through the antibody reaction chamber using finger-powered pressure actuation to initiate a hemagglutination reaction to identify the blood type at the on-chip detection area using our homemade CMOS image sensing mini-system. Finger-powered actuation without the need for external electrical pumping is excellent for low-cost POC applications, but the pumping liquid volume per finger push is hard to control. In our finger-powered agglutination lab chip with CMOS image sensing, we minimized the effects of different finger push depths and achieved robust performance for the test results with different push depths. The driving sample volume per finger push is about 0.79 mm3. For different chips and different pushes, the driven sample volume per finger push was observed to vary in the range of 0.64 to 1.18 mm3. The red blood cells were separated from the plasma on-chip after the whole blood sample was finger pumped and before the red blood cells reached the antibody chamber via an embedded plasma-separation membrane. Our homemade CMOS image mini-system robustly read and identified the agglutination results on our agglutination lab chip.
Collapse
Affiliation(s)
- Chung Hsiang Lu
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan, Republic of China.
| | - Ting-Sheng Shih
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan, Republic of China.
| | - Po-Chen Shih
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan, Republic of China.
| | - Gaurav Prashant Pendharkar
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan, Republic of China.
| | - Cheng-En Liu
- Department of Electrophysics, National Chiao-Tung University, Hsinchu, Taiwan 300, Republic of China
| | - Chi-Kuan Chen
- MacKay Memorial Hospital, New Taipei City, Taiwan, Republic of China
| | - Long Hsu
- Department of Electrophysics, National Chiao-Tung University, Hsinchu, Taiwan 300, Republic of China
| | - Hwan-You Chang
- Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan 300, Republic of China
| | - Chia-Ling Yang
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan, Republic of China.
| | - Cheng-Hsien Liu
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 30013, Taiwan, Republic of China.
| |
Collapse
|
12
|
Tanaka Y, Kumagi T, Terao T, Kuroda T, Yokota T, Azemoto N, Imamura Y, Uesugi K, Kisaka Y, Shibata N, Koizumi M, Ohno Y, Kanemitsu K, Yukimoto A, Tange K, Nishiyama M, Miyake T, Miyata H, Ishii H, Abe M, Hiasa Y. ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. Intern Med 2020; 59:761-768. [PMID: 32173688 PMCID: PMC7118372 DOI: 10.2169/internalmedicine.3748-19] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Objective The long-term effect of the ABO blood type on the clinical course of patients with pancreatic cancer (PC) is inconclusive. This study aimed to determine whether or not the ABO blood type influences the long-term outcomes of PC in Japanese patients. Methods The medical records of Japanese patients with PC were reviewed. Data, including the age, sex, and outcomes, from the Ehime Pancreato-Cholangiology Study Group were analyzed. Results The mean age of the 406 patients was 71.0±10.5 years, and 220 (54.2%) were men. A total of 44.6%, 20.7%, 22.4%, and 12.3% had blood type A, B, O, and AB, respectively. The median survival time (MST) of patients with A alleles was shorter than that of patients with non-A alleles (p=0.048), especially among those who underwent resection (p=0.031). In contrast, no marked difference in the MST was noted among those who underwent chemotherapy and palliative care. Finally, a multivariate analysis confirmed A alleles as an independent factor associated with the long-term outcome of PC (p<0.05 in 2 different models). Conclusion The ABO blood type influenced the long-term outcomes of Japanese patients with PC, presumably due to its impact on disease onset and tumor behavior.
Collapse
Affiliation(s)
- Yoshinori Tanaka
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
- Gastroenterology, Matsuyama Shimin Hospital, Japan
| | - Teru Kumagi
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Takashi Terao
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
- Gastroenterology, National Hospital Organization Shikoku Cancer Center, Japan
| | - Taira Kuroda
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Tomoyuki Yokota
- Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Japan
| | - Nobuaki Azemoto
- Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Japan
- Gastroenterology, Ehime Prefectural Central Hospital, Japan
| | - Yoshiki Imamura
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Kazuhiro Uesugi
- Gastroenterology, National Hospital Organization Shikoku Cancer Center, Japan
- Gastroenterology, Uwajima Municipal Hospital, Japan
| | | | - Naozumi Shibata
- Internal Medicine, Ehime Prefectural Niihama Hospital, Japan
| | - Mitsuhito Koizumi
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Yoshinori Ohno
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Kozue Kanemitsu
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Atsushi Yukimoto
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
- Gastroenterology, Uwajima Municipal Hospital, Japan
| | - Kazuhiro Tange
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
- Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Japan
| | | | - Teruki Miyake
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Hideki Miyata
- Gastroenterology, Ehime Prefectural Central Hospital, Japan
| | - Hiroshi Ishii
- Gastroenterology, National Hospital Organization Shikoku Cancer Center, Japan
| | - Masanori Abe
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| | - Yoichi Hiasa
- Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan
| |
Collapse
|
13
|
Song Q, Wu JZ, Wang S, Chen ZB. The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer. J Cancer 2019; 10:6754-6760. [PMID: 31777605 PMCID: PMC6856877 DOI: 10.7150/jca.36236] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Accepted: 08/26/2019] [Indexed: 01/01/2023] Open
Abstract
Previous studies have suggested a relationship between ABO blood group and clinical outcome of various cancers. Nevertheless, little is known about the association between ABO blood group and survival in patients with ovarian carcinoma. This study aimed to investigate the prognostic significance of ABO blood group in patients with ovarian carcinoma. 941 patients who were newly diagnosed with ovarian carcinoma between February 2007 and February 2016 were enrolled in the present study. The relationship between ABO blood type and clinical features in patients with ovarian cancer was analyzed using chi-square tests. Overall survival (OS) stratified by B antigen was evaluated using log-rank test and Kaplan-Meier method. Presence of the B antigen (B/AB) had a worse OS than those in the absence of the B antigen (A/O) in all patients with ovarian cancer, especially in patients with FIGO stage I, IV, and menopause. Presence of the B antigen (B/AB) was significantly correlated with OS than those with non-B antigen (A/O) (hazard ratios 1.342; 95% confidence interval 1.069-1.685; P=0.011). Multivariate analyses revealed that presence of the B antigen (B/AB) was independently associated with OS (hazard ratios 1.532; 95% confidence interval 1.111-2.112; P=0.009). This study indicated that presence of the B antigen (B/AB) was an unfavorable prognostic factor in ovarian carcinoma, especially in patients with FIGO stage I, IV, and menopause.
Collapse
Affiliation(s)
- Qian Song
- Department of Clinical Laboratory, Institute of cancer research and basic medical sciences of Chinese Academy of Sciences, Cancer hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China
| | - Jun-Zhou Wu
- Cancer Research Institute, Institute of cancer research and basic medical sciences of Chinese Academy of Sciences, Cancer hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China
| | - Sheng Wang
- Department of Clinical Laboratory, Institute of cancer research and basic medical sciences of Chinese Academy of Sciences, Cancer hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China
| | - Zhong-Bo Chen
- Department of Gynecologic Oncology, Institute of cancer research and basic medical sciences of Chinese Academy of Sciences, Cancer hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China
| |
Collapse
|
14
|
Wang GN, Zhou S, Chen C, Chang H, Tao Y, Liu S, Wang XH, Zhang WW, Liu Y, Liu SR, Ding SR, Yang X, Ye ZQ, Gao YF, Xia YF. O Blood Type Is Associated with Unfavorable Distant-metastasis-free Survival in Female Patients with Nasopharyngeal Carcinoma: A Retrospective Study of 2439 Patients from Epidemic Area. J Cancer 2019; 10:1297-1306. [PMID: 30854139 PMCID: PMC6400674 DOI: 10.7150/jca.28372] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2018] [Accepted: 01/02/2019] [Indexed: 01/02/2023] Open
Abstract
Purpose: To identify the association between ABO blood type and the survivals in nasopharyngeal carcinoma patients. Patients and methods: We retrospectively analyzed 2439 consecutive non-metastasis nasopharyngeal carcinoma patients between January 2001 and December 2004 at the Sun Yat-sen University Cancer Center. Survival outcomes were compared using Kaplan-Meier method. Univariate and multivariate analysis was performed by Cox regression model. Chi-square test was performed to compare categorical variables. Results: In the whole patients, compared with non-O blood type (A, B, and AB) patients, O blood type patients had significantly lower 5-year distant metastasis-free survival (DMFS) (adjusted hazard ratio (aHR)= 1.268, 95% CI 1.010-1.592, P=0.041). Moreover, we observed in female patients, O blood type patients had significantly lower 5-year overall survival (OS), disease-specific survival (DSS) and DMFS than those with non-O blood type (aHR=1.495, 95% CI 1.032-2.165, P=0.034 for OS; aHR=1.566, 95% CI 1.054-2.328, P=0.026 for DSS; aHR=1.779, 95% CI 1.056-2.998, P=0.030 for DMFS). In male patients, there was no significant difference observed between O blood type patients and non-O blood type patients in any survival endpoints. Conclusion: O blood type was associated with an unfavorable DMFS in female patients with nasopharyngeal carcinoma in epidemic area, which might contribute to unfavorable OS and DSS in female patients, even contribute to a lower DMFS in the whole patients. It might be beneficial to predict metastasis so as to guide the treatment in female patients with nasopharyngeal carcinoma in epidemic area.
Collapse
Affiliation(s)
- Guan-Nan Wang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Shu Zhou
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Chen Chen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Hui Chang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Yalan Tao
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Shan Liu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Xiao-Hui Wang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Wen-Wen Zhang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Yang Liu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Song-Ran Liu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Shi-Rong Ding
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Xin Yang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Zheng-Qian Ye
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| | - Yi-Feng Gao
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, P. R. China
| | - Yun-Fei Xia
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.,Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
| |
Collapse
|
15
|
Arslan B, Gürkan O, Çetin B, Arslan ÖA, Göv T, Yazıcı G, Eroglu T, Avcı MA, Ozdemir E. Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma. Int Urol Nephrol 2018; 50:2131-2137. [PMID: 30324575 DOI: 10.1007/s11255-018-2012-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Accepted: 10/11/2018] [Indexed: 12/23/2022]
Abstract
PURPOSE The aim of our study was to investigate the impact of the ABO blood groups and blood-based biomarkers on the growth kinetics of renal angiomyolipoma (AML). METHODS A total of 124 patients with AML who were followed-up between 2010 and 2018 were retrospectively reviewed. The patients' characteristics were recorded, including age, body mass index (BMI), blood pressure, smoking history, and ABO blood group. Baseline laboratory test results, including serum creatinine, AST, ALT, platelet, neutrophil and lymphocyte count, were used to calculate the estimated glomerular filtration rate (eGFR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and De Ritis ratio. The Cox regression analysis was used to evaluate the relationship between variables and tumor growth. RESULTS The study population comprised 71 women and 44 men with a median age of 47.3 (28-65) years. Among patients classified according to the blood groups, no significant differences were observed regarding age, BMI, smoking history, co-morbidities, NLR, PLR, De Ritis ratio, eGFR, or tumor size and localisation. The mean growth rate from baseline to the last scan was 0.36 ± 0.27 cm, 0.21 ± 0.21 cm, 0.14 ± 0.11 cm, and 0.19 ± 0.17 cm for blood type O, A, B, and AB, respectively. In multivariate analysis, eGFR < 60 (p = 0.044), central tumor localisation (p = 0.030), presence of blood group-0 (p = 0.038), and De Ritis ratio ≥ 1.24 (p = 0.047) were statistically associated with tumor growth. CONCLUSION Our study demonstrates that both the ABO blood groups and the De Ritis ratio might represent independent predictors of tumor growth rate in patients with renal AML.
Collapse
Affiliation(s)
- Burak Arslan
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey.
| | - Okan Gürkan
- Department of Radiology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey
| | - Bugra Çetin
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey
| | - Öykü Aksoy Arslan
- Department of Haematology, Istanbul Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey
| | - Taha Göv
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey
| | - Gökhan Yazıcı
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey
| | - Tolga Eroglu
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey
| | - Mustafa Asım Avcı
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey
| | - Enver Ozdemir
- Department of Urology, Istanbul Taksim Gaziosmanpasa Training and Research Hospital, Karayolları Str. No:621, Gaziosmanpaşa, Istanbul, Turkey
| |
Collapse
|
16
|
Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman DA, Razorenova OV. Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism. Mol Cancer Ther 2018; 17:1781-1792. [PMID: 29720560 PMCID: PMC6072609 DOI: 10.1158/1535-7163.mct-17-1076] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 11/19/2017] [Accepted: 04/24/2018] [Indexed: 01/05/2023]
Abstract
Clear cell renal cell carcinoma (CC-RCC) is a devastating disease with limited therapeutic options available for advanced stages. The objective of this study was to investigate HMG-CoA reductase inhibitors, also known as statins, as potential therapeutics for CC-RCC. Importantly, treatment with statins was found to be synthetically lethal with the loss of the von Hippel-Lindau (VHL) tumor suppressor gene, which occurs in 90% of CC-RCC driving the disease. This effect has been confirmed in three different CC-RCC cell lines with three different lipophilic statins. Inhibition of mevalonate synthesis by statins causes a profound cytostatic effect at nanomolar concentrations and becomes cytotoxic at low micromolar concentrations in VHL-deficient CC-RCC. The synthetic lethal effect can be fully rescued by both mevalonate and geranylgeranylpyrophosphate, but not by squalene, indicating that the effect is due to disruption of small GTPase isoprenylation and not the inhibition of cholesterol synthesis. Inhibition of Rho and Rho kinase (ROCK) signaling contributes to the synthetic lethality effect, and overactivation of hypoxia-inducible factor signaling resulting from VHL loss is required. Finally, statin treatment is able to inhibit both tumor initiation and progression of subcutaneous 786-OT1-based CC-RCC tumors in mice. Thus, statins represent potential therapeutics for the treatment of VHL-deficient CC-RCC. Mol Cancer Ther; 17(8); 1781-92. ©2018 AACR.
Collapse
Affiliation(s)
- Jordan M Thompson
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - Alejandro Alvarez
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - Monika K Singha
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - Matthew W Pavesic
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - Quy H Nguyen
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - Luke J Nelson
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - David A Fruman
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California
| | - Olga V Razorenova
- Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California.
| |
Collapse
|
17
|
Stakišaitis D, Juknevičienė M, Ulys A, Žaliūnienė D, Stanislovaitienė D, Šepetienė R, Slavinska A, Sužiedėlis K, Lesauskaitė V. ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity. Oncol Lett 2018; 16:1321-1331. [PMID: 30061952 PMCID: PMC6063046 DOI: 10.3892/ol.2018.8749] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Accepted: 04/16/2018] [Indexed: 02/07/2023] Open
Abstract
The aim of the present study was to assess the ABO blood group polymorphism association with prostate, bladder and kidney cancer, and longevity. The following data groups were analyzed: Prostate cancer (n=2,200), bladder cancer (n=1,530), renal cell cancer (n=2,650), oldest-old (n=166) and blood donors (n=994) groups. The data on the ABO blood type frequency and odds ratio in prostate cancer patients revealed a significantly higher blood group B frequency (P<0.05); the pooled men and women, separate men bladder cancer risk was significantly associated with the blood group B (P<0.04); however, no such association was identified in the female patients. The blood group O was observed to have a significantly decreased risk of bladder cancer for females (P<0.05). No significance for the ABO blood group type in the studied kidney cancer patients was identified. A comparison of the oldest-old and blood donor groups revealed that blood group A was significantly more frequent and blood type B was significantly rarer in the oldest-olds (P<0.05). The results of the present study indicated that blood type B was associated with the risk of prostate and bladder cancer, and could be evaluated as a determinant in the negative assocation with longevity. Blood types O and A may be positive factors for increasing the oldest-old age likelihood. The clustering analysis by the ABO type frequency demonstrated that the oldest-olds comprised a separate cluster of the studied groups.
Collapse
Affiliation(s)
- Donatas Stakišaitis
- Laboratory of Molecular Oncology, National Cancer Institute, LT-08660 Vilnius, Lithuania
| | - Milda Juknevičienė
- Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | - Albertas Ulys
- Oncosurgery Clinics, National Cancer Institute, LT-08660 Vilnius, Lithuania
| | - Dalia Žaliūnienė
- Department of Ophtalmology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | - Daiva Stanislovaitienė
- Department of Ophtalmology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | - Ramunė Šepetienė
- Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | | | - Kęstutis Sužiedėlis
- Laboratory of Molecular Oncology, National Cancer Institute, LT-08660 Vilnius, Lithuania
| | - Vita Lesauskaitė
- Department of Geriatrics, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| |
Collapse
|
18
|
Seebacher V, Polterauer S, Reinthaller A, Koelbl H, Achleitner R, Berger A, Concin N. AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study. BMC Cancer 2018; 18:447. [PMID: 29673336 PMCID: PMC5909228 DOI: 10.1186/s12885-018-4289-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Accepted: 03/21/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND AB0 blood groups and Rhesus factor expression have been associated with carcinogenesis, response to treatment and tumor progression in several malignancies. The aim of the present study was to test the hypothesis that AB0 blood groups and Rhesus factor expression are associated with clinical outcome in patients with epithelial ovarian cancer (EOC). METHODS AB0 blood groups and Rhesus factor expression were evaluated in a retrospective multicenter study including 518 patients with EOC. Their association with patients' survival was assessed using univariate and multivariable analyses. RESULTS Neither AB0 blood groups nor Rhesus factor expression were associated with clinico-pathological parameters, recurrence-free, cancer-specific, or overall survival. In a subgroup of patients with high-grade serous adenocarcinoma, however, blood groups B and AB were associated with a better 5-year cancer-specific survival rate compared to blood groups A and 0 (60.3 ± 8.6% vs. 43.8 ± 3.6%, p = 0.04). Yet, this was not significant in multivariable analysis. CONCLUSIONS AB0 blood groups and Rhesus factor expression are both neither associated with features of biologically aggressive disease nor clinical outcome in patients with EOC. Further investigation of the role of the blood group B antigen on cancer-specific survival in the subgroup of high-grade serous should be considered.
Collapse
Affiliation(s)
- Veronika Seebacher
- Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center Vienna, Gynecologic Cancer Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
| | - Stephan Polterauer
- Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center Vienna, Gynecologic Cancer Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.,Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Franziskanergasse 4a, 3100, St. Pölten, Austria
| | - Alexander Reinthaller
- Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center Vienna, Gynecologic Cancer Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.,Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Franziskanergasse 4a, 3100, St. Pölten, Austria
| | - Heinz Koelbl
- Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center Vienna, Gynecologic Cancer Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria
| | - Regina Achleitner
- Department of Gynaecology and Obstetrics, Medical University of Innsbruck, Innrain 52, Christoph-Probst-Platz, 6010, Innsbruck, Austria
| | - Astrid Berger
- Department of Gynaecology and Obstetrics, Medical University of Innsbruck, Innrain 52, Christoph-Probst-Platz, 6010, Innsbruck, Austria
| | - Nicole Concin
- Department of Gynaecology and Obstetrics, Medical University of Innsbruck, Innrain 52, Christoph-Probst-Platz, 6010, Innsbruck, Austria
| |
Collapse
|
19
|
Xiao S, Feng F, Sun L, Cai L, Liu Z, Liu S, Fan D, Zhang H. Blood type AB predicts promising prognosis in gastric cancer patients with positive preoperative serum CEA. Medicine (Baltimore) 2017; 96:e8496. [PMID: 29381925 PMCID: PMC5708924 DOI: 10.1097/md.0000000000008496] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Little is known about association between ABO blood groups and tumor markers in gastric cancer (GC) patients. The aim of the present study was to assess the prognostic value of ABO blood groups in GC patients with different levels of preoperative serum carcinoembryonic antigen (CEA).From September 2008 to April 2015, a total of 3234 GC patients who received radical gastrectomy were retrospectively analyzed. The clinicopathological characteristics including ABO blood groups and preoperative CEA were recorded. The prognostic value of ABO blood groups within different levels of serum CEA was analyzed.Overall, the ratio of male to female patients was 3.5:1; the median age was 57.4 years (range 20-87). The median overall survival (OS) for GC patients with blood type A, B, AB, and O were 52.6, 52.8, 53.8, and 53.6 months, respectively. There was no significant difference for the survival of patients among the 4 groups (P = .736). Also, no significant difference was found among the OS of the 4 blood types with negative (P = .875) and positive (P = .131) preoperative serum CEA. Further, we found that the OS of patients with positive preoperative serum CEA and blood type AB was significantly higher than that with blood type non-AB (P = .026). For patients with positive preoperative serum CEA, multivariate analysis showed that ABO blood groups were an independent prognostic factor.Blood type AB was a favorable prognostic factor for GC patients with positive preoperative serum CEA.
Collapse
|
20
|
ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Sci Rep 2017; 7:4412. [PMID: 28667286 PMCID: PMC5493683 DOI: 10.1038/s41598-017-04046-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 05/25/2017] [Indexed: 12/23/2022] Open
Abstract
ABO blood types are associated with the prognosis of several malignancies. However, the role of the ABO blood type in hepatocellular carcinoma (HCC) remains elusive. Here, we evaluated the prognostic role of the ABO blood group in 691 HCC patients after hepatectomy by Cox regression analysis. A prognostic nomogram was generated to predict the 3 and 5-year overall survival (OS). A total of 262 HCC patients (37.9%) had blood group O, 199 (28.8%) had blood group A, 165 (23.9%) had blood group B, and 65 (9.4%) had blood group AB. The median OS was 55 months in patients with blood group O, 39 months for blood group A, 34 months for blood group B, and 34 months for blood group AB patients (P = 0.001, log-rank test). There were significant differences in OS between patients with blood groups O and A [hazard ratio (HR) = 1.416; 95% CI, 1.101–1.820; P = 0.007], blood group B (HR = 1.736; 95% CI, 1.333–2.262; P < 0.001), blood group AB (HR = 1.739; 95% CI, 1.210–2.499; P = 0.003) and non-O blood groups (HR = 1.485; 95% CI, 1.204–1.830; P < 0.001). Our constructed nomogram (c-index = 0.687) predicted the prognosis more accurately than the TNM stage alone(c-index = 0.601). In conclusion, non-O blood groups are poor prognostic indicators for HCC following hepatectomy. Our findings justify further external validation in larger cohorts.
Collapse
|
21
|
Ben Q, Liu J, Wang W, Guo F, Yao W, Zhong J, Yuan Y. Association between ABO blood types and sporadic pancreatic neuroendocrine tumors in the Chinese Han population. Oncotarget 2017; 8:54799-54808. [PMID: 28903383 PMCID: PMC5589622 DOI: 10.18632/oncotarget.18592] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Accepted: 05/27/2017] [Indexed: 12/20/2022] Open
Abstract
Background Although the relationship between non-O blood types and the risk of exocrine pancreatic cancer has been demonstrated, the association between ABO blood types and sporadic pancreatic neuroendocrine tumor (PNET) has not been reported thus far. Methods This hospital-based, case-control study included 387 patients with PNET and 542 age- and sex-matched controls. Unconditional multivariable logistic regression analysis was performed to estimate the adjusted odds ratios (AORs) and 95% confidence intervals (CIs). The relationship between ABO blood types and clinicopathologic features was also analyzed. Results After adjusting for age, sex, smoking status, alcohol drinking, and first-degree family history of any cancer, the AORs (95% CI) of functional PNET were 0.87 (0.59–1.28) for blood type A, 0.86 (0.58–1.28) for blood type B, and 0.71 (0.39–1.26) for blood type AB compared with subjects with blood type O. A similar ABO blood-type distribution was observed among cases with non-functional PNETs compared with controls. On comparing blood type B with non-B blood type, cases with non-functional PNETs had marginally higher rates of lymph node invasion (P = 0.047), distant metastasis (P = 0.044), and advanced European Neuroendocrine Tumor Society Stage (P = 0.040). Conclusions There is no association between the ABO blood group and the development of functional and non-functional PNETs. The ABO blood types are not associated with the clinicopathologic features in patients with functional and non-functional PNETs.
Collapse
Affiliation(s)
- Qiwen Ben
- Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Jun Liu
- Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Weiyi Wang
- Department of Endoscopy, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China
| | - Fang Guo
- Department of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Weiyan Yao
- Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Jie Zhong
- Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Yaozong Yuan
- Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
| |
Collapse
|
22
|
Omae K, Fukuma S, Ikenoue T, Kondo T, Takagi T, Ishihara H, Tanabe K, Fukuhara S. Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Urol Oncol 2017. [PMID: 28624136 DOI: 10.1016/j.urolonc.2017.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVES To assess the effect of blood type on survival outcomes and adverse events (AEs) in patients treated with tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS Patients who received TKIs as first-line therapy for mRCC between 2008 and 2015 at our hospital were included in the study (n = 136). Patients were divided into 2 groups based on their blood type as O and non-O. Survival outcomes and AEs were compared according to blood type. Cox regression models were used for univariate and multivariate survival analyses. RESULTS Of the 136 patients, 34 (25%) and 102 (75%) had O and non-O blood types, respectively. Blood type O was associated with an increased number of disease sites. There were no differences between the 2 groups with respect to other baseline characteristics. The progression-free survival in patients with O and non-O blood types was 12.1 and 11.6 months, respectively; the overall survival was 34.4 and 24.8 months, respectively. On univariate and multivariate analyses, the ABO blood type was not a significant prognostic factor for progression-free survival or overall survival. Furthermore, the incidences of serious AEs were similar in the 2 blood groups. CONCLUSIONS ABO blood type was not associated with survival outcomes or incidences of serious AEs in mRCC patients treated with TKIs. However, blood type O may be associated with an increased number of disease sites.
Collapse
Affiliation(s)
- Kenji Omae
- Department of Healthcare Epidemiology, Kyoto University School of Public Health, Kyoto, Japan; Fukushima Medical University, Center for Innovative Research for Communities and Clinical Excellence, Fukushima City, Fukushima, Japan; Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan
| | - Shingo Fukuma
- Department of Healthcare Epidemiology, Kyoto University School of Public Health, Kyoto, Japan; Fukushima Medical University, Center for Innovative Research for Communities and Clinical Excellence, Fukushima City, Fukushima, Japan
| | - Tatsuyoshi Ikenoue
- Department of Healthcare Epidemiology, Kyoto University School of Public Health, Kyoto, Japan
| | - Tsunenori Kondo
- Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan
| | - Toshio Takagi
- Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan
| | - Hiroki Ishihara
- Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan
| | - Kazunari Tanabe
- Department of Urology, Tokyo Women׳s Medical University, Tokyo, Japan.
| | - Shunichi Fukuhara
- Department of Healthcare Epidemiology, Kyoto University School of Public Health, Kyoto, Japan; Fukushima Medical University, Center for Innovative Research for Communities and Clinical Excellence, Fukushima City, Fukushima, Japan
| |
Collapse
|
23
|
Chen Z, Shao Y, Wang K, Cao W, Xiong Y, Wu R, Luo S, Xu X, He X. Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther 2016; 9:6701-6710. [PMID: 27822073 PMCID: PMC5094571 DOI: 10.2147/ott.s108469] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Recently, many studies have shown that pretreatment serum albumin can be closely linked to the prognosis of cancer patients, including those with renal cell carcinoma (RCC). However, not all studies have reached the same conclusion. We therefore conducted a systematic review and meta-analysis to evaluate the prognostic value of pretreatment serum albumin in RCC patients. A total of 17 studies involving 6,447 patients were included in our meta-analysis. Our results indicated that a lower pretreatment serum albumin level yielded a worse overall survival (hazard ratio [HR]=2.46, 95% confidence interval [CI] 1.92–3.13), cancer-specific survival (HR=2.22, 95% CI 1.87–2.64), and relapse-free survival/progression-free survival (HR=1.75, 95% CI 1.28–2.38). Generally, these findings were particularly pronounced when stratified by tumor type, analysis type, cut-off value, and HR-obtaining method. In conclusion, a decreased pretreatment serum albumin level implies a poor prognosis for RCC patients, and can be monitored for risk stratification and individualized treatment in RCC patients.
Collapse
Affiliation(s)
- Zhen Chen
- Department of Urology, The Third Affiliated Hospital of Soochow University
| | - Yingjie Shao
- Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou
| | - Kun Wang
- Department of Urology, The Third Affiliated Hospital of Soochow University
| | - Wei Cao
- Department of Urology, The Third Affiliated Hospital of Soochow University
| | - Yulong Xiong
- Department of Urology, The Third Affiliated Hospital of Soochow University
| | - Rongzu Wu
- Department of Urology, The Third Affiliated Hospital of Soochow University
| | - Shicheng Luo
- Department of Urology, The Third Affiliated Hospital of Soochow University
| | - Xianlin Xu
- Department of Urology, Sir Run Run Shaw Hospital, Third Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China
| | - Xiaozhou He
- Department of Urology, The Third Affiliated Hospital of Soochow University
| |
Collapse
|
24
|
Jin T, Li PJ, Chen XZ, Hu WH. ABO blood group is a predictor of survival in patients with laryngeal cancer. CHINESE JOURNAL OF CANCER 2016; 35:90. [PMID: 27733208 PMCID: PMC5062923 DOI: 10.1186/s40880-016-0152-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 09/27/2016] [Indexed: 01/11/2023]
Abstract
Background Whether the ABO blood group is associated with the survival of patients with laryngeal cancer remains unknown. The purpose of this study was to investigate the association between the ABO blood group and clinicopathologic characteristics of patients with laryngeal cancer and assess whether the ABO blood group was associated with prognosis. Methods We analyzed the records of 1260 patients with laryngeal cancer who underwent curative treatment at Sun Yat-sen University Cancer Center between January 1993 and December 2009. The Chi-square test was used to assess the relationship between the ABO blood group and clinicopathologic characteristics. The Kaplan–Meier method was used to estimate 3-, 5-, and 10-year overall survival (OS) rates. The Cox proportional hazards model was used in univariate and multivariate analyses of OS. Results No significant association was found between the ABO blood group and clinicopathologic characteristics except for primary tumor site. The median OS for patients with blood groups A, B, AB, and O were 87.0, 80.0, 90.0, and 72.5 months, respectively. The 3-, 5-, and 10-year OS rates were 82.4%, 76.0%, and 67.5% for patients with blood group A; 77.4%, 69.8%, and 58.4% for patients with blood group B; 82.2%, 73.1%, and 65.6% for patients with blood group AB; and 71.7%, 66.4%, and 55.5% for patients with blood group O, respectively. Univariate and multivariate analyses showed that the ABO blood group had significant effects on prognosis in patients with laryngeal cancer. Conclusions The ABO blood group is associated with survival in patients with laryngeal cancer. Patients with blood group O had significantly shorter OS than patients with other ABO blood groups.
Collapse
Affiliation(s)
- Ting Jin
- Key Laboratory of Radiation Oncology in Zhejiang Province, Hangzhou, 310022, Zhejiang, P. R. China.,Department of Radiation Oncology, Zhejiang Cancer Hospital, 38 Guang Ji Road, Hangzhou, 310022, Zhejiang, P. R. China
| | - Pei-Jing Li
- State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China
| | - Xiao-Zhong Chen
- Key Laboratory of Radiation Oncology in Zhejiang Province, Hangzhou, 310022, Zhejiang, P. R. China. .,Department of Radiation Oncology, Zhejiang Cancer Hospital, 38 Guang Ji Road, Hangzhou, 310022, Zhejiang, P. R. China.
| | - Wei-Han Hu
- State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China.
| |
Collapse
|
25
|
Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urol Oncol 2016; 34:256.e7-256.e13. [DOI: 10.1016/j.urolonc.2015.12.016] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 12/26/2015] [Accepted: 12/28/2015] [Indexed: 01/17/2023]
|
26
|
Gershman B, Moreira DM, Tollefson MK, Frank I, Cheville JC, Thapa P, Tarrell RF, Thompson RH, Boorjian SA. The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Urol Oncol 2016; 34:4.e1-9. [DOI: 10.1016/j.urolonc.2015.07.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 06/19/2015] [Accepted: 07/12/2015] [Indexed: 01/12/2023]
|
27
|
Chen JY, Huang YT, Chou HH, Wang CP, Chen CF. Rapid and inexpensive blood typing on thermoplastic chips. LAB ON A CHIP 2015; 15:4533-41. [PMID: 26530285 DOI: 10.1039/c5lc01172h] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
A portable and cost-effective colorimetric diagnostic device was fabricated for rapid ABO and Rh blood typing. Using microfluidic construction on a thermoplastic chip, blood antibodies were preloaded into a reaction channel and exposed to blood samples to initiate a haemagglutination reaction. Downstream high-aspect ratio filters, composed of 2 μm high microslits, block agglutinated red blood cells (RBCs) to turn the reaction channel red, indicating the presence of the corresponding blood antigen. Users manually actuate the blood sample using a simple screw pump that drives the solution through serpentine reaction channels and chaotic micromixers for maximum interaction of the preloaded antibodies with the blood sample antigens. Mismatched RBCs and antibodies elute from the channel into an outlet reservoir based on the rheological properties of RBCs with no colorimetric change. As a result, unambiguous blood typing tests can be distinguished by the naked eye in as little as 1 min. Blood disorders, such as thalassemia, can also be distinguished using the device. The required blood volume for the test is just 1 μL, which can be obtained by the less invasive finger pricking method. The low reagent consumption, manual driving force, low-cost of parts, high yield, and robust fabrication process make this device sensitive, accurate, and simple enough to use without specialized training in resource constrained settings.
Collapse
Affiliation(s)
- Jun-You Chen
- Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung 402, Taiwan.
| | | | | | | | | |
Collapse
|
28
|
Hanprasertpong J, Jiamset I, Atjimakul T. Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection. Tumour Biol 2015; 37:7421-30. [PMID: 26678885 DOI: 10.1007/s13277-015-4626-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 12/10/2015] [Indexed: 11/25/2022] Open
Abstract
This study aimed to evaluate the prognostic value of ABO blood groups in early-stage cervical cancer patients. The cohort included 413 patients diagnosed with stages IA2-IB1 cervical cancer who received a radical hysterectomy between 2002 and 2014. The 5-year recurrence-free survival (RFS) and overall survival (OS) were 93.13 and 96.81 % for blood group O, 87.68 and 88.22 % for blood group A, 81.66 and 89.40 % for blood group B, and 83.12 and 94.12 % for blood group AB groups, respectively. Patients were stratified for analysis as either blood group O or non-O. The 5-year RFS and OS were 93.13 and 96.81 % for blood group O and 83.66 and 89.76 % for blood group non-O, respectively. In multivariate analysis, age (P = 0.025), histology (P = 0.020), and deep stromal invasion (P = 0.006) were independent adverse prognostic factors for RFS, while the statistically significant independent prognostic factors for OS were age (P = 0.007) and parametrial involvement (P < 0.001). The Cox model did not show any significant effects of non-O blood group on survival outcome. However, a time-varying-effect Cox model revealed that the non-O blood group was associated with a worse RFS (hazard ratio (HR) 2.69, 95 % confidence interval (95%CI) 1.12-6.46, P = 0.017) and OS (HR 3.13, 95%CI 0.88-11.16, P = 0.053) during the first 5 years. These findings suggest that early-stage cervical cancer patients with a non-O blood group have poorer RFS than the O blood group, which is evidence during the first 5 years.
Collapse
Affiliation(s)
- Jitti Hanprasertpong
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, 90110, Thailand.
| | - Ingporn Jiamset
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, 90110, Thailand
| | - Thiti Atjimakul
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, 90110, Thailand
| |
Collapse
|
29
|
The prognostic value of ABO blood group in cancer patients. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2015; 14:434-40. [PMID: 26674825 DOI: 10.2450/2015.0164-15] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 07/28/2015] [Indexed: 12/20/2022]
Abstract
The antigens of the ABO system are expressed on red blood cell membranes as well as on the surface of several other normal and pathological cells and tissues. Following the first clinical observations more than 60 years ago, the role of ABO blood group in cancer biology has been intensely studied by several investigators, and it is now widely recognised that ABO antigens are associated with the risk of developing several types of tumours, namely pancreatic and gastric cancers. However, whether this association also affects the clinical outcome of cancer patients is less certain. In this narrative review, based on literature data, we discuss the role of ABO blood types as prognostic biomarkers in different types of cancers. The current knowledge of the underlying pathogenic mechanisms of the association is also analysed.
Collapse
|
30
|
Wang W, Liu L, Wang Z, Wei M, He Q, Ling T, Cao Z, Zhang Y, Wang Q, Shi M. Impact of ABO blood group on the prognosis of patients undergoing surgery for esophageal cancer. BMC Surg 2015; 15:106. [PMID: 26420728 PMCID: PMC4588230 DOI: 10.1186/s12893-015-0094-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 09/23/2015] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND ABO blood type is an established prognostic factor in several malignancies, but its role in esophageal cancer (EC) is largely unknown. The aim of this study is to determine whether ABO blood group is associated with survival after esophagectomy for EC. METHODS A total of 406 patients who underwent surgery for EC were enrolled. The associations of ABO blood group with clinical and pathological variables were assessed using chi-square test. Associations of ABO blood group with the survival were estimated using univariable and multivariable Cox proportional hazards regression models. RESULTS The ABO blood group proportionally associated with the grade of EC tumor (P = 0.049). The ABO blood group status did not correlate with disease-free survival (DFS) in univariable analysis or multivariable analysis (P > 0.05). And there was no significant relationship between the ABO blood group and overall survival (OS) in univariable analysis or multivariable analysis (P > 0.05). CONCLUSIONS Our results suggested that no association between ABO blood group and the survival was observed in patients undergoing surgery for EC.
Collapse
Affiliation(s)
- Wei Wang
- Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
| | - Lei Liu
- Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
| | - Zhiwei Wang
- Department of Breast, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China. .,Department of Thoracic Surgery, Shanghai Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Min Wei
- Department of Breast, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Qi He
- Department of Breast, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Tianlong Ling
- Department of Thoracic Surgery, Shanghai Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ziang Cao
- Department of Thoracic Surgery, Shanghai Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yixin Zhang
- Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
| | - Qiang Wang
- Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
| | - Minxin Shi
- Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China.
| |
Collapse
|
31
|
Li N, Xu M, Li CF, Ou W, Wang BX, Zhang SL, Xu PF, Yuan C, Huang QA, Wang SY. Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center. CHINESE JOURNAL OF CANCER 2015; 34:475-82. [PMID: 26411553 PMCID: PMC4593379 DOI: 10.1186/s40880-015-0054-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Accepted: 09/13/2015] [Indexed: 12/12/2022]
Abstract
Background A positive association between the ABO blood types and survival has been suggested in several malignancies. The aim of this study was to assess the role of the ABO blood types in predicting the prognosis of Chinese patients with curatively resected non-small cell lung cancer (NSCLC). Methods We retrospectively analyzed 1601 consecutive Chinese patients who underwent curative surgery for NSCLC between January 1, 2005 and December 31, 2009. The relationship between the ABO blood types and survival was investigated. In addition, univariate and multivariate analyses were performed. Results Group 1 (patients with the blood type O or B) had significantly prolonged overall survival (OS) compared with group 2 (patients with the blood type A or AB), with a median OS of 74.9 months versus 61.5 months [hazard ratio (HR) 0.83; 95% confidence interval (CI) 0.72–0.96; P = 0.015]. Additionally, group 1 had significantly longer disease-free survival (DFS; HR 0.86; 95% CI 0.76–0.98; P = 0.022) and locoregional relapse-free survival (LRFS; HR 0.79; 95% CI 0.64–0.98; P = 0.024) than group 2. The association was not significantly modified by other risk factors for NSCLC, including smoking status, pathologic tumor-node-metastasis stage, pT category, pN category, and chemotherapy. Conclusions There is an association between the ABO blood types and the survival of Chinese patients with resected NSCLC. Patients with the blood type O or B had significantly prolonged OS, DFS, and LRFS compared with those with the blood type A or AB.
Collapse
Affiliation(s)
- Ning Li
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Miao Xu
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Chao-Feng Li
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Information Technology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Wei Ou
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Bao-Xiao Wang
- Breast Tumor Center, Sun Yat-sen Memorial Hospital, Guangzhou, 510120, Gaungdong, P.R. China.
| | - Song-Liang Zhang
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Peng-Fei Xu
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Cheng Yuan
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Qun-Ai Huang
- Department of Thyroid and Breast Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, Guangdong, P.R. China.
| | - Si-Yu Wang
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| |
Collapse
|
32
|
Steplewski Z, Thurin M, Kieber-Emmons T. Antibodies: At The Nexus of Antigens and Cancer Vaccines. J Infect Dis 2015; 212 Suppl 1:S59-66. [PMID: 26116735 DOI: 10.1093/infdis/jiu638] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
This review describes the development of monoclonal antibodies and the inception of their use in cancer therapy, their impact on defining cancer biomarkers, and their structural utility in new cancer vaccine development.
Collapse
Affiliation(s)
| | - Magdalena Thurin
- Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Thomas Kieber-Emmons
- Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock
| |
Collapse
|
33
|
Engel O, Soave A, Peine S, Kluth LA, Schmid M, Shariat SF, Dahlem R, Fisch M, Rink M. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol 2015; 33:1769-76. [DOI: 10.1007/s00345-015-1531-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 03/05/2015] [Indexed: 11/25/2022] Open
|
34
|
Abstract
Human ABO blood group antigens are expressed on the surface of red blood cells and a variety of human cells and tissues. However, an increasingly number of studies show that the ABO blood group, in addition to its fundamental role in transfusion medicine and in several other disciplines, has a causal role in predisposing to several human diseases, including hemostasis and neoplastic disorders, which will be the focus of this narrative review.
Collapse
|
35
|
Lee C, You D, Sohn M, Jeong IG, Song C, Kwon T, Hong B, Hong JH, Ahn H, Kim CS. Prognostic value of ABO blood group in patients with renal cell carcinoma: single-institution results from a large cohort. J Cancer Res Clin Oncol 2015; 141:1441-7. [PMID: 25687379 DOI: 10.1007/s00432-015-1908-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 01/04/2015] [Indexed: 12/20/2022]
Abstract
OBJECTIVES To evaluate the association between ABO blood group and prognosis in patients with renal cell carcinoma (RCC) undergoing surgery. MATERIALS AND METHODS A review of the nephrectomy database of the Asan Medical Center identified 3,172 consecutive patients who underwent nephrectomy for RCC between 1997 and 2012. Patients were followed up for a median 60.2 months (interquartile range 33-102 months). Recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) were calculated by the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards regression model was used to estimate the prognostic significance of each variable. RESULTS Of these 3,172 patients, 915 (28.8 %), 1,057 (33.7 %), 860 (26.7 %) and 340 (10.8 %) were blood types O, A, B, and AB, respectively. ABO blood group was not associated with age, sex, operation method, American Society of Anesthesiologists physical status classification, histologic subtype, or pathological TNM stage. The 5-year OS rates in patients with blood types O, A, B, and AB were 86.0, 86.8, 86.6, and 88.6 %, respectively, and the 10-year OS rates were 78.7, 78.6, 79.1, and 76.9 %, respectively (P = 0.990). ABO blood group was not significantly associated with RFS (P = 0.921) or CSS (P = 0.808). Univariable and multivariable analyses showed that ABO blood group was not a significant prognostic factor of RFS, CSS, or OS. CONCLUSIONS Our study found that ABO blood group is not associated with survival outcomes and is not a prognostic factor in patients who underwent surgery for RCC.
Collapse
Affiliation(s)
- Chunwoo Lee
- Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-Gil, Songpa-gu, Seoul, 138-736, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Kaffenberger SD, Lin-Tsai O, Stratton KL, Morgan TM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol 2015; 33:21.e11-21.e17. [PMID: 25456998 PMCID: PMC4274038 DOI: 10.1016/j.urolonc.2014.10.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Accepted: 10/13/2014] [Indexed: 12/13/2022]
Abstract
PURPOSE To determine whether statin use at time of surgery is associated with survival following nephrectomy or partial nephrectomy for renal cell carcinoma (RCC). Statins are thought to exhibit a protective effect on cancer incidence and possibly cancer survival in a number of malignancies. To date, no studies have shown an independent association between statin use and mortality in RCC. METHODS A retrospective cohort study of 916 patients who underwent radical or partial nephrectomy for RCC from 2000 to 2010 at a single institution was performed. Primary outcomes were overall (OS) and disease-specific survival (DSS). Univariable survival analyses were performed using the Kaplan-Meier and the log-rank methods. Multivariable analysis was performed using a Cox proportional hazards model. The predictive discrimination of the models was assessed using the Harrell c-index. RESULTS The median follow-up of the entire cohort was 42.5 months. The 3-year OS estimate was 83.1% (95% CI: 77.6%-87.3%) for statin users and 77.3% (95% CI: 73.7%-80.6%) for nonstatin users (P = 0.53). The 3-year DSS was 90.9% (95% CI: 86.3%-94.0%) for statin users and 83.5% (95% CI: 80.1%-86.3%) for nonstatin users (P = 0.015). After controlling for age, American Society of Anesthesiology class, pT category, pN category, metastatic status, preoperative anemia and corrected hypercalcemia, and blood type, statin use at time of surgery was independently associated with improved OS (hazard ratio = 0.62; 95% CI: 0.43-0.90; P = 0.011) and DSS (hazard ratio = 0.48; 95% CI: 0.28-0.83; P = 0.009). The multivariable model for DSS had excellent predictive discrimination with a c-index of 0.91. CONCLUSIONS These data suggest that statin usage at time of surgery is independently associated with improved OS and DSS in patients undergoing surgery for RCC.
Collapse
Affiliation(s)
- Samuel D Kaffenberger
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN.
| | - Opal Lin-Tsai
- Vanderbilt University School of Medicine, Nashville, TN
| | - Kelly L Stratton
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN; Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Todd M Morgan
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN; Department of Urology, University of Michigan Health System, Ann Arbor, MI
| | - Daniel A Barocas
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN; Center for Surgical Quality and Outcomes Research, Vanderbilt University Medical Center, Nashville, TN
| | - Sam S Chang
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Michael S Cookson
- Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK
| | - S Duke Herrell
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Joseph A Smith
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Peter E Clark
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
37
|
Fukumoto K, Taniguchi T, Usami N, Kawaguchi K, Fukui T, Ishiguro F, Nakamura S, Yokoi K. The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer. J Epidemiol 2014; 25:110-6. [PMID: 25483106 PMCID: PMC4310871 DOI: 10.2188/jea.je20140102] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Background The ABO blood group is reported to be associated with the incidence and patient survival for several types of malignancies. We conducted a retrospective study to evaluate the prognostic significance of the ABO blood group in patients with resected non-small cell lung cancer (NSCLC). Methods A total of 333 patients (218 men and 115 women) with resected NSCLC were included in this study. In addition to age, sex, smoking status, preoperative serum carcinoembryonic antigen (CEA) level, operative procedure, histology of tumors, pathological stage (p-stage), and adjuvant therapy, the association between the ABO blood group and survival was explored. Results The 5-year overall and disease-free survival rates were 83.0% and 71.6% for blood group O, 67.2% and 62.3% for blood group A, 68.8% and 68.8% for blood group B and 69.2% and 65.3% for blood group AB, respectively. A multivariate analysis for overall survival showed the ABO blood group (group A vs. group O: HR 2.47, group AB vs. group O: HR 3.62) to be an independent significant prognostic factor, in addition to age, sex, smoking status, p-stage, and serum CEA level. A multivariate analysis for disease-free survival also showed the ABO blood group to be an independent significant prognostic factor. Conclusions The ABO blood group is an independent prognostic factor in patients with resected NSCLC. Studies of other larger cohorts are therefore needed to confirm the relationship between the ABO blood group and the prognosis among patients with resected NSCLC.
Collapse
Affiliation(s)
- Koichi Fukumoto
- Department of Thoracic Surgery, Nagoya University Graduate School of Medicine
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Sun P, Chen C, Zhang F, An X, Li XY, Li YH, Zhu ZH, Wang FH. The ABO blood group predicts survival in esophageal squamous cell carcinoma in patients who ever smoked: a retrospective study from China. Tumour Biol 2014; 35:7201-8. [PMID: 24771222 DOI: 10.1007/s13277-014-1960-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2014] [Accepted: 04/10/2014] [Indexed: 12/17/2022] Open
Abstract
The association between clinical characteristics, prognosis, and the ABO blood group of esophageal squamous cell carcinoma (ESCC) is rarely discussed. The aims of the current study were to investigate the correlation of the ABO blood group with the clinicopathological characteristics in a consecutive cohort of patients with ESCC and to assess whether the ABO blood group was associated with prognosis. A total of 511 patients with locoregional ESCC who underwent curative treatment were retrospectively analyzed at a single institution between January 2007 and December 2008. The relationship between the ABO blood group and clinicopathological variables was assessed by chi-squared analysis. The Kaplan-Meier method was used to estimate the 5-year overall survival (OS). The Cox proportional hazards model was used in univariate and multivariate analyses of OS. There were no significant differences in the clinicopathological characteristics among patients with different ABO blood groups. The 5-year OS rates were 50.0 % for patients with blood type A, 45.4 % for type B, 50.8 % for type O, and 60.7 % for type AB. In a subgroup analysis of 321 patients who ever smoked, the B/O group had a poorer OS compared with the A/AB group (p = 0.0245). Multivariate analysis revealed an unfavorable and independent impact of the B/O group on patient survival with ESCC who ever smoked (p = 0.011). Findings suggest the B/O blood type as a predictor of mortality in ESCC patients who ever smoked. Future studies conducted prospectively are warranted to confirm this work and to better understand the underlying biological mechanisms.
Collapse
Affiliation(s)
- Peng Sun
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, 510060, Guangzhou, Guangdong Province, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Süer E, Özcan C, Gökçe I, Gülpınar Ö, Göğüş C, Türkölmez K, Baltacı S, Bedük Y. Do blood groups have effect on prognosis of patients undergoing radical cystectomy? Int Urol Nephrol 2014; 46:1521-6. [PMID: 24677002 DOI: 10.1007/s11255-014-0698-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Accepted: 03/18/2014] [Indexed: 12/18/2022]
Abstract
PURPOSE The purpose of the study was to investigate the effect of ABO blood groups and Rhesus (Rh) factor on prognosis of patients undergoing radical cystectomy. MATERIALS AND METHODS In this study, total number of 290 patients who underwent radical cystectomy between January 1990 and September 2012 were evaluated retrospectively. Patients were grouped as O and non-O according to ABO antigens; also positive and negative according to Rh factor. Parameters such as age, sex, stage, lymph node involvement and positive surgical margins were investigated. Disease-free and overall survival rates have been compared. Multivariate analysis were performed to determine independent prognostic factors. RESULTS A total of 260 (89.7 %) male and 30 (10.3 %) female patients participated in the study. Mean follow-up was 37.7 ± 18.9 months. A total of 180 patients were non-O (62.1 %),while the 110 patients had the blood group O (37.9 %). The number of Rh positive and negative patients were 247 (85.2 %) and 43 (14.8 %), respectively. According to the univariate and multivariate analyses, ABO blood groups and Rh factor did not exhibit any significant impact on overall and disease-specific survival. CONCLUSION ABO blood group and Rh factor were not associated with the prognosis of bladder cancer patients who underwent radical cystectomy. However, prospective studies are needed in larger patient series for further evaluations.
Collapse
Affiliation(s)
- Evren Süer
- Department of Urology, Ibn-i Sina Hospital, Ankara University, Samanpazarı-Ankara, 06100, Turkey,
| | | | | | | | | | | | | | | |
Collapse
|
40
|
de Martino M, Waldert M, Haitel A, Schatzl G, Shariat SF, Klatte T. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). BJU Int 2013; 113:E62-6. [PMID: 24053513 DOI: 10.1111/bju.12436] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVE To evaluate ABO blood group as a prognostic marker in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS This retrospective study included 556 consecutive patients who underwent surgery for RCC at a single institution. The associations of ABO blood group with clinical and pathological variables were assessed using Kruskal-Wallis and chi-squared tests. The impact on overall survival (OS) and RCC-specific survival (RCC-SS) was analysed using univariable and multivariable Cox proportional hazards regression models. RESULTS Blood group O was associated with the absence of lymph node metastases (P = 0.034) and the presence of bilateral RCC (P = 0.017). No associations with age, gender, body mass index, Charlson comorbidity index, T stage, M stage, grade and histological subtype were observed. In univariable and multivariable survival analysis, ABO blood group was not associated with OS and RCC-SS. CONCLUSIONS In the present study, ABO blood group was not linked with RCC prognosis. Blood group O may be associated with the absence of lymph node metastases and the presence of bilateral RCC. External validation in larger cohorts is necessary.
Collapse
|
41
|
Wang JK, Boorjian SA, Frank I, Tarrell RF, Thapa P, Jacob EK, Tauscher CD, Tollefson MK. Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology 2013; 83:140-5. [PMID: 24139524 DOI: 10.1016/j.urology.2013.08.046] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 08/16/2013] [Accepted: 08/26/2013] [Indexed: 12/01/2022]
Abstract
OBJECTIVE To evaluate the association of blood type (non-O vs O) with venous thromboembolism (VTE) risk after radical cystectomy (RC) for bladder cancer. METHODS From 1980 to 2005, we identified 2076 consecutive patients with RC for whom blood type was available in 2008 (96.7%). We evaluated the association of blood type with postoperative VTE using logistic regression, controlling for patient age, tumor, and nodal stage, Eastern Cooperative Oncology Group (ECOG) performance status, body-mass index (BMI), and number of lymph nodes removed at surgery. RESULTS A total of 865 of 2076 patients (41.7%) had O blood type, 1143 (55.0%) were non-O, and 68 (3.3%) were missing. Median follow-up was 11.1 years, during which time VTE developed in 216 patients (10.4%). No significant differences were noted between those with O vs non-O blood type regarding patient age (median 69 years vs 69, P = .87), ECOG (P = .69), BMI (median 27.5 vs 28.1, P = .12), tumor stage (P = .97), pN+ status (15.6% vs 15.2%, P = .79), or number of nodes removed (median 9 vs 8, P = .43). On multivariate analysis, non-O blood type was associated with a nearly two-fold increased risk of VTE (odds ratio [OR] = 1.85, P = .007). CONCLUSION Non-O blood type was independently associated with an increased risk of VTE after RC. These patients should be counseled accordingly, and may benefit from increased perioperative prophylaxis.
Collapse
Affiliation(s)
| | | | - Igor Frank
- Department of Urology, Mayo Clinic, Rochester, MN
| | - Robert F Tarrell
- Division of Health Care Policy & Research, Mayo Clinic, Rochester, MN
| | - Prabin Thapa
- Division of Health Care Policy & Research, Mayo Clinic, Rochester, MN
| | - Eapen K Jacob
- Division of Transfusion Medicine, Mayo Clinic, Rochester, MN
| | | | | |
Collapse
|
42
|
Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013; 109:2462-6. [PMID: 24022193 PMCID: PMC3817319 DOI: 10.1038/bjc.2013.559] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Revised: 08/17/2013] [Accepted: 08/19/2013] [Indexed: 11/29/2022] Open
Abstract
Background: ABO blood group is associated with aetiology of nasopharyngeal carcinoma (NPC); however, the effect of it on survival of patients diagnosed with NPC has not been explored. Methods: We retrospectively analysed two cohorts of southern Chinese patients with WHO histological type III: intensity-modulated radiotherapy (IMRT) cohort, 924 patients; and conventional radiotherapy (CRT) cohort, 1193 patients. Associations of ABO blood group with survival were estimated using Cox regression. Results: In IMRT cohort, we observed significant associations of blood type A with overall survival (OS) and distant metastasis-free survival (DMFS), compared with type O, after adjusting for prognostic factors. Compared with non-A blood types (B, AB, and O), type A patients had significantly lower OS and DMFS (adjusted hazard ratio (HR)=1.49, 95% CI 1.03–2.17, P=0.036; HR=1.68, 95% CI 1.13–2.51, P=0.011, respectively); similar results were obtained in CRT cohort. Subgroup analyses of the entire population showed that lower OS conferred by blood type A was not significantly modified by age, smoking status, drinking status, immunoglobulin A against Epstein–Barr virus viral capsid antigen (VCA-IgA) titre, or chemotherapy; however, lower OS was not observed in female patients or patients with early clinical stage disease. Conclusion: ABO blood group is associated with survival in NPC; patients with blood type A had significantly lower OS and DMFS than patients with non-A blood types.
Collapse
|